Conflict of Interest Policies for Organizations Producing a Large Number of Clinical Practice Guidelines

被引:44
作者
Norris, Susan L. [1 ]
Holmer, Haley K. [1 ]
Burda, Brittany U. [2 ]
Ogden, Lauren A. [1 ]
Fu, Rongwei [3 ]
机构
[1] Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Portland, OR 97201 USA
[2] Kaiser Permanente Ctr Hlth Res, Portland, OR USA
[3] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97201 USA
来源
PLOS ONE | 2012年 / 7卷 / 05期
基金
美国医疗保健研究与质量局;
关键词
PHARMACEUTICAL-INDUSTRY; CONCLUSIONS; AUTHORS; ASSOCIATION; QUALITY; TRIALS;
D O I
10.1371/journal.pone.0037413
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: Conflict of interest (COI) of clinical practice guideline (CPG) sponsors and authors is an important potential source of bias in CPG development. The objectives of this study were to describe the COI policies for organizations currently producing a significant number of CPGs, and to determine if these policies meet 2011 Institute of Medicine (IOM) standards. Methodology/Principal Findings: We identified organizations with five or more guidelines listed in the National Guideline Clearinghouse between January 1, 2009 and November 5, 2010. We obtained the COI policy for each organization from publicly accessible sources, most often the organization's website, and compared those polices to IOM standards related to COI. 37 organizations fulfilled our inclusion criteria, of which 17 (46%) had a COI policy directly related to CPGs. These COI policies varied widely with respect to types of COI addressed, from whom disclosures were collected, monetary thresholds for disclosure, approaches to management, and updating requirements. Not one organization's policy adhered to all seven of the IOM standards that were examined, and nine organizations did not meet a single one of the standards. Conclusions/Significance: COI policies among organizations producing a large number of CPGs currently do not measure up to IOM standards related to COI disclosure and management. CPG developers need to make significant improvements in these policies and their implementation in order to optimize the quality and credibility of their guidelines.
引用
收藏
页数:12
相关论文
共 43 条
[1]  
Academy of Breastfeeding Medicine, 2010, COD INT CO
[2]   Task force 1: The ACCF and AHA codes of conduct in human subjects research [J].
Alpert, JS ;
Shine, KI ;
Adams, RJ ;
Antman, EM ;
Kavey, REW ;
Friedman, L ;
Frye, RL ;
Harrington, RA ;
Korn, D ;
Merz, JF ;
Ofili, E .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 44 (08) :1724-1728
[3]   Association of funding and conclusions in randomized drug trials - A reflection of treatment effect or adverse events? [J].
Als-Nielsen, B ;
Chen, WD ;
Gluud, C ;
Kjaergard, LL .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (07) :921-928
[4]  
American Association for the Study of Liver Diseases, 2009, POL DEV US PRACT GUI
[5]  
American College of Obstetricians and Gynecologists, 2011, AM COLL OBST GYN CON
[6]  
American Diabetes Association, AM DIAB ASS POL STAT
[7]  
American Urological Association, 2011, PRINC POL PROC MAN C
[8]  
[Anonymous], 2017, NATION
[9]  
[Anonymous], 2008, US PREV SERV TASK FO
[10]   Why review articles on the health effects of passive smoking reach different conclusions [J].
Barnes, DE ;
Bero, LA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (19) :1566-1570